Durata Therapeutics, Inc. Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI  
12/11/2012 10:41:07 AM

CHICAGO--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced preliminary, top-line results for its DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).